StockData
Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd (RDY) stock

RDYNYSEPharmaceutical PreparationsFiscal year ends March 31
Financials through fiscal 2026, year ended Mar 31, 2026Score 7/30
$14.89+0.06 (+0.40%)

Close on Nov 20, 2026Market cap $12.43BP/E 27.3Yield 0.57%

Dr Reddys Laboratories gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

For fiscal 2026 it was ₹177.26B, down 6.9% from the year before. Over ten years it grew 6.7% a year on average. The highest annual figure on record is ₹190.43B in fiscal 2025.

Annual gross profit

PeriodPeriod endValueChange
FY2026Mar 31, 2026₹177.26B-6.9%
FY2025Mar 31, 2025₹190.43B+16.4%
FY2024Mar 31, 2024₹163.61B+17.4%
FY2023Mar 31, 2023₹139.34B+22.4%
FY2022Mar 31, 2022₹113.84B+10.4%
FY2021Mar 31, 2021₹103.08B+9.6%
FY2020Mar 31, 2020₹94.01B+12.7%
FY2019Mar 31, 2019₹83.43B+9.3%
FY2018Mar 31, 2018₹76.30B-2.6%
FY2017Mar 31, 2017₹78.36B-15.1%
FY2016Mar 31, 2016₹92.28B–

More Dr Reddys Laboratories figures

See a number that looks wrong?